Bioengineered PLGA-chitosan nanoparticles for brain targeted intranasal delivery of antiepileptic TRH analogues

Kaur, Sarabjit; Manhas, Priya; Swami, Anuradha; Bhandari, Ranjana; Sharma, Krishna K.; Jain, Rahul; Kumar, Ravinder; Pandey, Satish Kumar; Kuhad, Anurag; Sharma, Rohit K.; Wangoo, Nishima

doi:10.1016/j.cej.2018.03.176

Cited by 64 publications

(37 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason for this difference was that CB had a lower molecular weight and fewer reactive groups than BSA. However, the sizes of both nanoparticles were less than 200 nm, and the nanoparticles were thus suitable for nose‐to‐brain delivery . To further confirm the formation of CB‐Gd‐Cy5.5 and BSA‐Gd‐Cy5.5 nanoparticles, the particle morphologies were characterized using SEM, AFM, and TEM imaging as shown in Figure b,c,e,f; and Figure S1, Supporting Information, which indicated the presence of spherical aggregates and was consistent with the abovementioned data.…”

Section: Resultssupporting

confidence: 79%

Efficient Cholera Toxin B Subunit‐Based Nanoparticles with MRI Capability for Drug Delivery to the Brain Following Intranasal Administration

Chen

Fan

et al. 2018

Macromolecular Bioscience

View full text Add to dashboard Cite

Alzheimer's disease (AD) is an incurable neurodegenerative brain disorder that exhibits clear pathologic changes in the hippocampus. Traditional drug delivery systems are ineffective due to the existence of the blood–brain barrier (BBB). In this study, an efficient, stable, and easily constructed nanosystem (CB‐Gd‐Cy5.5) based on the cholera toxin B subunit (CB) is designed to improve the efficiency of drug delivery to the brain, especially the hippocampus. Through intranasal administration, CB‐Gd‐Cy5.5 is easily delivered to the brain without intervention by the BBB. The CB in CB‐Gd‐Cy5.5 is used for specifically combining with the monosialoganglioside GM1, which is widely found in the hippocampus. This nanosystem exhibits impressive performance in accumulating in the hippocampus. In addition, the good magnetic resonance imaging (MRI) capability of CB‐Gd‐Cy5.5 can satisfy the monitoring of AD in the different stages.

show abstract

Section: Resultssupporting

confidence: 79%

Efficient Cholera Toxin B Subunit‐Based Nanoparticles with MRI Capability for Drug Delivery to the Brain Following Intranasal Administration

Chen

Fan

et al. 2018

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…The results demonstrated a higher amount of drug permeated to the brain when the nanoparticles were coated with the polymer. Furthermore, mucoadhesion at nasal mucosa suggested a high permanence of the nanosystem, with a release profile longer than 48 h [20][21][22]. Similar findings were observed with polymeric nanoparticles administered via intranasal to treat conditions such as cerebral ischemia (PLC nanoparticles) [23,24], for nociceptive pain (PLA (poly-lactide acid) nanoparticles) [90], or to transport neuroprotective molecules such as coenzyme Q10, or contrast agents (PLGA nanoparticles).…”

Section: Chitosan-decorated Nanoparticles For Brain Targetingsupporting

confidence: 57%

“…Chitosan is a polymer natural widely utilized in different applications and approved for human use; it is a biodegradable, biocompatible, non-toxic, non-allergenic, and low-priced biomaterial; thus, chitosan is a suitable material for medical purposes [15]. Numerous studies have evaluated chitosan-coated nanosystems for the transportation of therapeutic compounds for the potential treatment of Alzheimer´s disease, Parkinson's disease, gliomas, cerebral ischemia, and schizophrenia [16][17][18][19][20][21][22][23][24].…”

Section: Introductionmentioning

confidence: 99%

A Reevaluation of Chitosan-Decorated Nanoparticles to Cross the Blood-Brain Barrier

et al. 2020

View full text Add to dashboard Cite

The blood-brain barrier (BBB) is a sophisticated and very selective dynamic interface composed of endothelial cells expressing enzymes, transport systems, and receptors that regulate the passage of nutrients, ions, oxygen, and other essential molecules to the brain, regulating its homeostasis. Moreover, the BBB performs a vital function in protecting the brain from pathogens and other dangerous agents in the blood circulation. Despite its crucial role, this barrier represents a difficult obstacle for the treatment of brain diseases because many therapeutic agents cannot cross it. Thus, different strategies based on nanoparticles have been explored in recent years. Concerning this, chitosan-decorated nanoparticles have demonstrated enormous potential for drug delivery across the BBB and treatment of Alzheimer’s disease, Parkinson’s disease, gliomas, cerebral ischemia, and schizophrenia. Our main objective was to highlight the high potential of chitosan adsorption to improve the penetrability through the BBB of nanoformulations for diseases of CNS. Therefore, we describe the BBB structure and function, as well as the routes of chitosan for crossing it. Moreover, we define the methods of decoration of nanoparticles with chitosan and provide numerous examples of their potential utilization in a variety of brain diseases. Lastly, we discuss future directions, mentioning the need for extensive characterization of proposed nanoformulations and clinical trials for evaluation of their efficacy.

show abstract

“…For decades, delivering imaging or therapeutic agents through the blood–brain barrier has been a serious challenge in diseases such as epilepsy, and the use of nanoparticles helps scientists to overcome this limitation. For instance, Kaur et al reported on an engineered PLGA–chitosan nanoparticle used to transport anti-epileptic TRH analogs targeted to the brain through intranasal delivery 39…”

Section: Discussionmentioning

confidence: 99%

<p>Novel nanosized AS1411–chitosan–BODIPY conjugate for molecular fluorescent imaging</p>

Taki¹,

Ardestani²

2019

IJN

View full text Add to dashboard Cite

Background: In recent years, non-invasive imaging technologies for early cancer detection have drawn worldwide attention. In this study, an antinucleolin aptamer, AS1411, was successfully conjugated to BODIPY-labeled chitosan and studied on T47D and HEK-293 cell lines. Methods: After conjugation of the aptamer to chitosan nanoparticles and purification, its structure was confirmed using atomic force microscopy (AFM), electrophoretic light scattering (ELS) and dynamic light scattering (DLS). Results of AFM, DLS and ELS of both conjugation and chitosan were compared for confirmation of conjugation. Conjugates were mixed with BODIPY FL fluorescent dye, purified and lyophilized. The labeled conjugate was characterized using Fourier-transform infrared spectroscopy, ultraviolet–visible spectroscopy, ELS and DLS. In vitro cellular uptake and cytotoxic effects of BODIPY-labeled chitosan–AS1411 aptamer conjugates were evaluated using the XTT assay on T47D and HEK-293 cells and flow cytometry on T47D cells. Results: The data showed that uptake of BODIPY-labeled chitosan–AS1411 aptamer conjugate was satisfactory. Moreover, there was no statistically significant cytotoxicity of the conjugate on either cell line. Conclusion: The outcomes confirmed the potential application of this new targeted imaging agent as a novel cancer diagnostic agent for molecular imaging.

show abstract

Bioengineered PLGA-chitosan nanoparticles for brain targeted intranasal delivery of antiepileptic TRH analogues

Cited by 64 publications

References 31 publications

Efficient Cholera Toxin B Subunit‐Based Nanoparticles with MRI Capability for Drug Delivery to the Brain Following Intranasal Administration

Efficient Cholera Toxin B Subunit‐Based Nanoparticles with MRI Capability for Drug Delivery to the Brain Following Intranasal Administration

A Reevaluation of Chitosan-Decorated Nanoparticles to Cross the Blood-Brain Barrier

<p>Novel nanosized AS1411–chitosan–BODIPY conjugate for molecular fluorescent imaging</p>

Contact Info

Product

Resources

About